DBV Technologies Appoints Philina Lee, Ph.D. to Board of Directors

DBV Technologies has announced the appointment of Dr. Philina Lee as an independent director on its Board of Directors, effective October 30, 2025. Dr. Lee replaces Daniel Soland, pending shareholder ratification at the next annual meeting. She will also join the Compensation Committee. This appointment brings the total number of board members to ten.

Philina Lee comes with significant experience from Blueprint Medicines, where she served as Chief Commercial Officer, leading the launch of AYVAKIT®. She also held board positions at Fusion Pharmaceuticals. Her addition is expected to strengthen DBV as it advances the VIASKIN® Peanut treatment for children with peanut allergies.

Dr. Lee expressed her enthusiasm about joining DBV, acknowledging the company's pivotal moment in advancing treatments for peanut allergies. She looks forward to contributing to the firm's growth and success.